$LEXX News

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7

Lexaria Bioscience Receives Ethics Approval For Human GLP-1 Study Comparing Oral DehydraTECH-Semaglutide Formulations To Wegovy, With Dosing Expected To Begin In Mid-June

Lexaria Updates Progress on Human Study #7

Lexaria Bioscience Advances Human Study Of DehydraTECH-Semaglutide Versus Wegovy Tablets

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Extends Pharma Partnership Through 2026 To Advance GLP-1 Research And DehydraTECH Licensing Potential

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Bioscience Engages The Contract Research Organization To Execute And Report On Its 2026 Animal Study #2 That Will Evaluate A Number Of Formulation Enhancements With Two Next-Generation GLP-1 Drugs In Animals

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely

Lexaria Engages CRO To Execute, Report On 2026 Animal Study GLP-1-A26-1 Evaluating Formulation Enhancements Using Both DHT-Sema GLP-1 And DHT-CBD Compositions To Explore Potential For Additional Improved Performance And Stake New IP Claims

Lexaria Bioscience Q2 EPS $(0.06) Beats $(0.11) Estimate, Sales $20.000K Miss $100.000K Estimate

Lexaria to Begin New Human Clinical Study in GLP-1

Lexaria Bioscience To Initiate New, Five-Week Human Clinical Study To Evaluate 2 Oral DehydraTECH-Semaglutide Compositions Against Wegovy

Lexaria's Robust Patent Portfolio Continues to Grow

Lexaria Bioscience Receives 5 New Patents Including 2 For Diabetes Treatment Utilizing GLP-1 Drugs

Lexaria's Oral GLP-1 Drug Strategy Validated by Industry

Lexaria Announces New R&D Plans for 2026